Optimal use of current therapeutic opportunities for chronic myeloid leukemia patients
requires integration of clinical and laboratory monitoring. Assessment of molecular response …

Tyrosine kinase inhibitor (TKI) therapy results in excellent responses in the majority of
patients with chronic myeloid leukaemia. First-line imatinib treatment, with selective …

We examined the involvement of sphingosine kinase-1 (SphK1), which governs the
ceramide/sphingosine-1-phosphate balance, in susceptibility to imatinib of either sensitive …

Resistance against tyrosine kinase inhibitors (TKIs) represents a relevant clinical problem in
treatment of chronic myelogenous leukemia (CML). On the basis of their activity against the …

The introduction of tyrosine kinase inhibitors (TKIs) directed against the catalytic activity of
the ABL tyrosine kinase has considerably improved the outcome of chronic myeloid …

Mutations in the drug binding region of BCR-ABL lead to imatinib resistance during the
management of chronic myeloid leukemia (CML). In our study, 62 Philadelphia positive …

Small molecule therapy is a critical component of targeted anticancer treatment, with
tyrosine kinase inhibitors (TKIs) being the first compounds to treat the clonal Chronic …

In this article, we are reviewing the molecular mechanisms that lead to kinase inhibitor
resistance. As the oncogenic BCR-ABL kinase is the target of the first approved small …

Background Breast cancer stem cells (BCSCs) have been recognized as playing a major
role in various aspects of breast cancer biology. To identify specific biomarkers of BCSCs …

Abstract Treatment of chronic myeloid leukemia (CML) with the tyrosine kinase inhibitors
(TKIs) imatinib mesylate and nilotinib represents a successful application of molecularly …